2021
Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure
Stravitz RT, Fontana RJ, Meinzer C, Durkalski‐Mauldin V, Hanje AJ, Olson J, Koch D, Hamid B, Schilsky M, McGuire B, Ganger D, Liou I, Karvellas CJ, Rule JA, Lisman T, Clasen K, Reuben A, Cripps M, Lee WM, Group A. Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure. Hepatology 2021, 74: 937-949. PMID: 33636020, PMCID: PMC10668528, DOI: 10.1002/hep.31767.Peer-Reviewed Original ResearchConceptsALI/ALFROTEM parametersRotational thromboelastometryDisease severityAcute liver injury/failureAbnormal hemostatic profileSevere systemic complicationsAcute liver injuryBleeding eventsBleeding riskLiver transplantationSystemic complicationsHemostatic failureLiver injuryIllness severityNative liverAbnormal hemostasisHemostatic profileStudy groupHigh incidencePatientsNormal rangeLaboratory evidenceClot formationClot stability
2015
Prospective Pilot Study of a Single Daily Dosage of Trientine for the Treatment of Wilson Disease
Ala A, Aliu E, Schilsky ML. Prospective Pilot Study of a Single Daily Dosage of Trientine for the Treatment of Wilson Disease. Digestive Diseases And Sciences 2015, 60: 1433-1439. PMID: 25605552, PMCID: PMC4427615, DOI: 10.1007/s10620-014-3495-6.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedChelating AgentsDrug Administration ScheduleFemaleHepatolenticular DegenerationHumansMaleMedication AdherenceMiddle AgedPatient DropoutsPatient SatisfactionPilot ProjectsProspective StudiesSurveys and QuestionnairesTime FactorsTreatment OutcomeTrientineYoung AdultConceptsSingle daily doseWilson's diseaseDaily doseDaily treatment regimenStable Wilson's diseaseProspective pilot studyLiver synthetic functionSingle daily dosageEnd of treatmentResultsAll patientsMaintenance therapyTreatment regimenDaily dosageLifelong therapyLarge trialsZinc excretionUrine copperTreatment stoppageSide effectsTreatment efficacyTrientineTherapyPatientsPilot studyDisease
2013
Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study
Chung R, Gordon F, Curry M, Schiano T, Emre S, Corey K, Markmann J, Hertl M, Pomposelli J, Pomfret E, Florman S, Schilsky M, Broering T, Finberg R, Szabo G, Zamore P, Khettry U, Babcock G, Ambrosino D, Leav B, Leney M, Smith H, Molrine D. Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study. American Journal Of Transplantation 2013, 13: 1047-1054. PMID: 23356386, PMCID: PMC3618536, DOI: 10.1111/ajt.12083.Peer-Reviewed Original ResearchConceptsLiver transplantationHepatitis C virusViral reboundViral loadPlacebo-controlled pilot studyAntibody-treated groupDays of transplantResistance-associated variantsHCV genotype 1aHuman monoclonal antibodyAllograft infectionRibavirin therapyPlacebo groupActing antiviralsPlacebo treatmentMedian timeViral clearanceSingle infusionC virusHCV E2Median changeGenotype 1aLimited efficacyDay 1Day 3
2005
Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry.
Kowdley K, Brandhagen D, Gish R, Bass N, Weinstein J, Schilsky M, Fontana R, McCashland T, Cotler S, Bacon B, Keeffe E, Gordon F, Polissar N. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005, 129: 494-503. PMID: 16083706, DOI: 10.1016/j.gastro.2005.05.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnalysis of VarianceCause of DeathCohort StudiesConfidence IntervalsFemaleGenetic MarkersGenotypeHemochromatosisHistocompatibility Antigens Class IHumansIron OverloadLiver Function TestsLiver TransplantationMaleMiddle AgedMutationProbabilityPrognosisProportional Hazards ModelsRegistriesSensitivity and SpecificitySeverity of Illness IndexSurvival AnalysisConceptsHepatic iron overloadHepatic iron indexHepatic iron concentrationLiver transplantationIron overloadPosttransplantation survivalC282Y/H63D mutationsEnd-stage liver diseaseHFE gene testingHFE mutation statusLiver transplantation centerNon-HH patientsOrgan Sharing statusYear of transplantationWild-type patientsPostliver transplantationTransplant RegistryHazard ratioTransplantation centersUncontrolled studiesLiver diseasePoor outcomeUnited NetworkIron indicesEarly diagnosis